Observational Study in Patients Treated With JAK Inhibitors for Inflammatory Rheumatism (MAJIK) (MAJIK)
JAKINIB Study: 'Observational', Multicentre Trial Collecting Prospective and On-going Clinical and Laboratory Data for Patients Treated With JAK Inhibitors for Inflammatory Rheumatism According to EMA.
Sponsor: Bordeaux PharmacoEpi
A observational or N/A phase clinical study on Inflammatory Rheumatism and Psoriatic Arthritis, this trial is ongoing. The trial is conducted by Bordeaux PharmacoEpi and has accumulated 10 data snapshots since 2019. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
10 versions recorded-
Sep 2025 — Present [monthly]
Active Not Recruiting
-
Jun 2025 — Sep 2025 [monthly]
Active Not Recruiting
-
Feb 2025 — Jun 2025 [monthly]
Active Not Recruiting
Status: Recruiting → Active Not Recruiting
-
Sep 2024 — Feb 2025 [monthly]
Recruiting
-
Jul 2024 — Sep 2024 [monthly]
Recruiting
▶ Show 5 earlier versions
-
Apr 2024 — Jul 2024 [monthly]
Recruiting
-
Nov 2022 — Apr 2024 [monthly]
Recruiting
-
Sep 2021 — Nov 2022 [monthly]
Recruiting
-
Jan 2021 — Sep 2021 [monthly]
Recruiting
-
Nov 2020 — Jan 2021 [monthly]
Recruiting
First recorded
Oct 2019
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Bordeaux PharmacoEpi
- Societe Francaise de Rhumatologie
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Antibes, France , Bayonne, France , Belfort, France , Besançon, France , Bobigny, France , Bordeaux, France , Bourg-en-Bresse, France , Brest, France , Caen, France , Cannes, France and 41 more locations